Arcus Completes $107 Million C Round with China VC Participation

22:15 EST 13 Nov 2017 | ChinaBio Today

Arcus Biosciences, a Bay Area biotech, announced a $107 million Series C financing. The round was led by GV (formerly Google Ventures) and included participation from China investors Decheng Capital, BVF Partners and Hillhouse among others. Arcus will use the capital for two clinical programs: AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody for which Arcus in-licensed ex-China rights from WuXi Biologics and Harbin Gloria Pharma in a $816 million deal announced in August. More details....

Stock Symbols: (HK: 2269) (SHZ: 002437)

Share this with colleagues:

Original Article: Arcus Completes $107 Million C Round with China VC Participation


More From BioPortfolio on "Arcus Completes $107 Million C Round with China VC Participation"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...